Specify a stock or a cryptocurrency in the search bar to get a summary
Island Pharmaceuticals Ltd
ILAIsland Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a collaboration agreement with Monash University and National Cancer Institute IND. It also has a cooperative research and development agreement with the U.S. Army, Island in preparation for its Phase 2a/b clinical study for ISLA-101. Island Pharmaceuticals Limited was founded in 2017 and is based in Camberwell, Australia. Address: 697 Burke Road, Camberwell, VIC, Australia, 3124
Analytics
WallStreet Target Price
0.25 AUDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ILA
Dividend Analytics ILA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ILA
Stock Valuation ILA
Financials ILA
Results | 2019 | Dynamics |